SEC Form 4 · accession 0001225208-26-006263
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel J. Lippis
Officer — CVP, TAVR
Period of report
Jun 30, 2026
Accepted (ET)
Jun 30, 2026 · 8:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | M | 619 | $72.68 | A | 41,030 | D | |
| Common StockF2 | Jun 30, 2026 | S | 619 | $91.4002 | D | 40,411 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire) | $72.68 | Jun 30, 2026 | M | 619 | D | May 7, 2021 | May 6, 2027 | Common Stock | 619 | 5,571 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.